Vanda Pharmaceuticals Inc. $VNDA Position Trimmed by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 53.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 148,757 shares of the biopharmaceutical company’s stock after selling 170,042 shares during the period. GSA Capital Partners LLP’s holdings in Vanda Pharmaceuticals were worth $1,312,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. AIGH Capital Management LLC acquired a new position in Vanda Pharmaceuticals during the 4th quarter valued at approximately $17,626,000. Hsbc Holdings PLC boosted its position in Vanda Pharmaceuticals by 17.6% during the 2nd quarter. Hsbc Holdings PLC now owns 66,554 shares of the biopharmaceutical company’s stock valued at $319,000 after purchasing an additional 9,960 shares during the period. PharVision Advisers LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth about $285,000. Algert Global LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth about $174,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth about $75,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on VNDA. HC Wainwright dropped their price objective on shares of Vanda Pharmaceuticals from $24.00 to $21.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wall Street Zen cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Monday, April 20th. Zacks Research cut shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Finally, Truist Financial began coverage on shares of Vanda Pharmaceuticals in a report on Thursday, March 5th. They issued a “buy” rating and a $18.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.30.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $6.18 on Thursday. The firm has a 50-day moving average price of $7.20 and a 200 day moving average price of $6.85. The firm has a market capitalization of $371.60 million, a PE ratio of -1.53 and a beta of 0.65. The company has a quick ratio of 2.15, a current ratio of 2.16 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals Inc. has a 52-week low of $4.14 and a 52-week high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). The company had revenue of $51.72 million during the quarter, compared to the consensus estimate of $54.98 million. Vanda Pharmaceuticals had a negative net margin of 109.99% and a negative return on equity of 32.26%. On average, sell-side analysts anticipate that Vanda Pharmaceuticals Inc. will post -2.27 earnings per share for the current fiscal year.

Insider Transactions at Vanda Pharmaceuticals

In related news, SVP Timothy Williams sold 42,434 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $8.27, for a total value of $350,929.18. Following the completion of the transaction, the senior vice president owned 377,450 shares in the company, valued at $3,121,511.50. This represents a 10.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Kevin Patrick Moran sold 42,442 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $8.27, for a total transaction of $350,995.34. Following the completion of the transaction, the chief financial officer owned 411,380 shares of the company’s stock, valued at $3,402,112.60. This represents a 9.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 314,342 shares of company stock worth $2,583,985 over the last ninety days. Insiders own 10.00% of the company’s stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.